HORMONE RECEPTOR POSITIVE TUMOR
Clinical trials for HORMONE RECEPTOR POSITIVE TUMOR explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE TUMOR trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could radio waves help shrink breast tumors before surgery?
Disease control Recruiting nowThis study tests a device called TheraBionic P1 that uses radio waves to target cancer cells. It is given to people with early-stage, hormone-positive, HER2-negative breast cancer before their surgery. The goal is to see if the device can reduce the number of cancer cells left in…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated May 16, 2026 22:34 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control Recruiting nowThis study is for premenopausal women with a common type of breast cancer (HR+/HER2-). It tests a drug called elacestrant, given alone or with another drug (triptorelin), for 4 weeks before surgery. The goal is to see if the treatment lowers a marker of cancer growth (Ki67) in th…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check the drug's safety, find the right dose, and se…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New pill aims to shrink tumors in advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests an experimental pill called INX-315 in 150 people with advanced cancers, including certain breast and ovarian cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study has three…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for hard-to-treat breast cancer: targeted combo enters phase 3
Disease control Recruiting nowThis study tests whether a new drug (RLY-2608) combined with fulvestrant works better than another approved combination (capivasertib + fulvestrant) for people with advanced or metastatic HR+/HER2- breast cancer that has a PIK3CA mutation. About 540 adults whose cancer worsened a…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New study tracks Pill-Taking habits in early breast cancer patients
Knowledge-focused Recruiting nowThis study looks at how well women with early-stage, hormone-positive breast cancer take their prescribed medications (aromatase inhibitors with or without abemaciclib). About 319 participants will be followed for 6 months to see if those on the combination therapy have lower adh…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated May 16, 2026 22:30 UTC
-
Can a simple test predict which breast cancer drug works best for you?
Knowledge-focused Recruiting nowThis study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Knowledge-focused
Last updated May 16, 2026 22:28 UTC